Latest Financial Obligations News

Vectus Biosystems has agreed to sell its VB4-P5 renal fibrosis compound to Canadian biotech XORTX Therapeutics for US$3 million in shares and warrants, gaining a strategic equity position while refocusing on its cardiovascular and fibrosis pipeline.

Cobalt Blue Holdings has fully repaid its $1 million promissory note to American Rare Earths, unencumbering its flagship Broken Hill Cobalt Project amid a strengthening cobalt market.

Cann Group Limited has extended the expiry of its NAB debt facilities by two weeks, providing a brief but vital window to advance its refinancing plans.

Avada Group Limited has adjusted its FY25 financial results following audit finalisation, increasing its income tax benefit and reclassifying borrowings, while confirming a strong financial position.

Linius Technologies has released its audited FY2025 financial statements, revealing non-cash accounting adjustments related to Convertible Notes that increased reported losses and liabilities compared to prior unaudited figures.

Beonic Ltd has raised $4.27 million through convertible notes to fund its product development, repay upcoming debt, and advance its North African Airport Project.

Klevo Rewards Limited has updated its prospectus to include a $4.1 million entitlement offer and a $2.2 million debt conversion, aiming to satisfy ASX reinstatement conditions after a prolonged suspension.

Morella Corporation has restructured its joint venture with Lithium Corporation, gaining 100% ownership of key Nevada lithium assets and streamlining its exploration portfolio.

CZR Resources has completed the sale of its Robe Mesa Iron Ore Project, netting over A$70 million and wiping out its debt. The company is now poised to accelerate exploration across its remaining Western Australian assets.

Rewardle Holdings clarifies its complex relationship with CloudHolter and updates on Pepper Leaf loan litigation, addressing ASX concerns over financial reporting delays.

Cann Group Limited has disclosed a late payment of over $1.37 million in interest and facility fees to National Australia Bank, which has issued a non-waiver letter but is holding off on immediate action. The company is actively negotiating financing arrangements and plans to update the market by the end of September 2025.

ALCORE, ABx Group’s subsidiary, has secured government approval for overseas R&D activities and is pursuing a $5 million grant to accelerate its clean fluorine chemical technology commercialisation.